Procter & Gamble Health Limited (PGHL.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹5,056.00 (+0.82%) as of
Key statistics
- Market cap
- 83.93B
- P/E (TTM)
- 23.50
- Forward P/E
- 20.54
- EPS (TTM)
- 215.19
- Dividend yield
- 3.09%
- 52-week range
- 4,707.00 – 6,975.00
- Beta
- 0.18
- Revenue (TTM)
- 14.33B
- Profit margin
- 24.91%
- Analyst target
- ₹7,090.00
- Volume
- 9.29k
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 1,276
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.